Among these MET aberrations, MET exon 14 skipping is one of the rare mutations in non-small cell lung cancer (NSCLC), accounting for 2–4% of lung adenocarcinoma pathogenesis and progression [2]. This evidence concerns the gene MET and non-small cell lung carcinoma.